{
  "docId": "019de073-cd7d-722a-8136-5a45a3cc0efe",
  "docSlug": "303c45082bb692ab214f73eda43168dc",
  "documentTitle": "NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "regulatory-filing",
  "documentKindLabel": "Regulatory filing",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 30,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "competitive_analysis",
  "function": "quantify_opportunity",
  "density": "overcrowded",
  "nDataPoints": 8,
  "notes": "The slide highlights rapid adoption compared to Saxenda and notes supply chain issues impacting Q4'21 and H1'22.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-cd7d-722a-8136-5a45a3cc0efe/24",
  "deckHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe",
  "deckJsonHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe.json",
  "deckAnchorHref": "/decks/019de073-cd7d-722a-8136-5a45a3cc0efe#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.48,
        "y": 0.53
      },
      "kind": "callout",
      "text": "In H1' 22 Novo Nordisk has been facing supply constraints thus affecting the ability to meet demand",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a3b38de-fda6-458a-b7bd-e2bdf7dad244",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.4,
        "y": 0.62
      },
      "kind": "callout",
      "text": "Q4' 21 contract manufacturer filling syringes stops deliveries and manufacturing due to quality concerns.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f477345-1cc3-4709-b300-318cf397b82f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.5,
        "x": 0.355,
        "y": 0.375
      },
      "kind": "chart",
      "text": "WEGOVY™ Sales ($M)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "02dc2e10-5167-4e2a-a68f-a75ae8392834",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "legend",
      "text": "As many prescriptions were written for WEGOVY™ as in the four years following launch of its predecessor SAXENDA®(1)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff6df345-87de-48b6-b247-0e68c15cdf66",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "In June 2021 the FDA approved WEGOVY™ (semaglutide) injection for chronic weight management in adults with obesity or overweight with at least one weight-related conditions (e.g. high blood pressure, T2DM, or high cholesterol).",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "929b40e5-e61a-4bd9-81ef-19888db6917d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1. Novo Nordisk A/S Form 20 filed on February 2, 2022; 2. Novo Nordisk A/S Q2 2022 Financial Results; 3. Estimated Q3' 22 and Q4' 22 sales based on the average analyst consensus per Bloomberg",
      "attrs": {
        "numbered": true
      },
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d9730596-64ed-4504-8254-feb87109470e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.5,
        "x": 0.05,
        "y": 0.03
      },
      "kind": "title",
      "text": "WEGOVY™ (Semaglutide) and Obesity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31e660ae-0128-43cc-b99f-a7cddf454778",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}